aTyr Pharma (NASDAQ:ATYR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

aTyr Pharma (NASDAQ:ATYR) posted its quarterly earnings data on Friday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01, FiscalAI reports. The company had revenue of $189.56 million for the quarter.

aTyr Pharma Stock Up 1.9%

Shares of NASDAQ:ATYR traded up $0.01 during trading on Friday, hitting $0.51. The stock had a trading volume of 355,761 shares, compared to its average volume of 1,115,501. aTyr Pharma has a 12-month low of $0.40 and a 12-month high of $6.50. The stock has a market capitalization of $50.14 million, a price-to-earnings ratio of -0.70 and a beta of 0.54. The stock has a 50-day simple moving average of $0.51 and a two-hundred day simple moving average of $0.70.

Insider Activity at aTyr Pharma

In other aTyr Pharma news, Director Paul Schimmel acquired 100,000 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were purchased at an average price of $0.50 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the director directly owned 779,143 shares of the company’s stock, valued at $389,571.50. The trade was a 14.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.75% of the stock is owned by company insiders.

Institutional Investors Weigh In On aTyr Pharma

Several hedge funds have recently added to or reduced their stakes in ATYR. Vanguard Group Inc. raised its stake in shares of aTyr Pharma by 21.0% during the 3rd quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock valued at $4,060,000 after buying an additional 975,887 shares during the last quarter. UBS Group AG boosted its stake in shares of aTyr Pharma by 158.1% during the 3rd quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock worth $3,249,000 after acquiring an additional 2,760,238 shares in the last quarter. Octagon Capital Advisors LP grew its position in shares of aTyr Pharma by 7.5% during the 2nd quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock valued at $19,367,000 after acquiring an additional 268,000 shares during the period. Geode Capital Management LLC grew its position in shares of aTyr Pharma by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock valued at $1,789,000 after acquiring an additional 105,514 shares during the period. Finally, Millennium Management LLC increased its stake in shares of aTyr Pharma by 22.0% in the 3rd quarter. Millennium Management LLC now owns 1,890,921 shares of the company’s stock valued at $1,364,000 after purchasing an additional 340,721 shares in the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Weiss Ratings downgraded shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 31st. Wall Street Zen raised shares of aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Freedom Capital upgraded shares of aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, aTyr Pharma has a consensus rating of “Hold” and a consensus price target of $17.00.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.